Actively Recruiting
Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic Adjustments
Led by University Hospital, Strasbourg, France · Updated on 2025-03-12
352
Participants Needed
1
Research Sites
206 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Inflammatory rheumatic diseases affect 1% of the population. Treatment of such diseases should be based on disease activity, safety issues and other patient characteristics such as comorbidities (EULAR, 2022), leading to a higher risk of cardiovascular diseases. To this end, the general treat-to-target approach, as recommended in the EULAR guidance, may require several successive treatment lines based on updates to the patients' profile and close monitoring as the keystone of its implementation. Regular feedback from patients could be used to fuel such strategies. This feedback can be collected using an ePRO (electronic Patient Reported Outcome). The purpose of this study is therefore to assess patient management using the information provided by patients through e-PROs, which will transfer the data provided by the patient to the physician and will notify the investigators via email when a patient has completed a form (no data interpretation or alerts). The hypothesis is that the more physicians are provided with insights into their patients' health, the more they will function in a treat-to-target approach and the more often they will tend to adjust their patients' treatments.
CONDITIONS
Official Title
Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic Adjustments
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men or women aged 18 years or older
- Diagnosed with at least one of the following autoimmune diseases: rheumatoid arthritis (2010 EULAR/ACR criteria), gout (2015 EULAR/ACR criteria), systemic lupus erythematosus (2019 EULAR/ACR criteria), or Sjogren's syndrome (2016 EULAR/ACR criteria)
- Provided written informed consent or expressed non-opposition to participate according to local regulations
- Have access to the internet, a working email address, and a mobile phone
- Physically and mentally able to use an internet-connected computer
- (Switzerland and Germany only) Covered by a health insurance plan
You will not qualify if you...
- Presence of any neurodegenerative disease that affects cognitive abilities
- Having refractory cancer
- Lack of access to or inability to use the internet as required by the study
- Unwillingness or inability to follow the study protocol due to language barriers or cognitive disorders
- Being compulsorily detained for psychiatric treatment
- Inability to be followed by the investigating physician for 2 years
- Being a vulnerable subject protected or deprived of liberty by judicial or administrative decision
- Having a life expectancy estimated to be less than 1 year
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital of Strasbourg
Strasbourg, France, 67000
Actively Recruiting
Research Team
J
Jacques-Eric GOTTENBERG, Professor
CONTACT
J
Jacques-Eric GOTTENBERG, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here